Canine Biologics

Canine Biologics

Early Stage

Our 2021 expansion brings breakthrough nutrition to more dogs with cancer

Our 2021 expansion brings breakthrough nutrition to more dogs with cancer

Overview

Raised to Date: Raised: $39,141

Total Commitments ($USD)

Platform

Netcapital

Start Date

09/08/2021

Close Date

03/08/2022

Min. Goal
$10,000
Max. Goal
$477,540
Min. Investment

$100

Security Type

Equity - Common

Series

Pre-Seed

SEC Filing Type

RegCF    Open SEC Filing

Price Per Share

$0.81

Pre-Money Valuation

$6,123,284

Rolling Commitments ($USD)

Status
Funded
Reporting Date

03/30/2022

Days Remaining
Funded
% of Min. Goal
Funded
% of Max. Goal
Funded
Likelihood of Max
Funded
Avg. Daily Raise

$217

Momentum
Funded
Create a free account today to gain access to KingsCrowd analytics.
Year Founded

2021

Industry

Pet Health, Food, and Services

Tech Sector

Biotech

Distribution Model

B2B/B2C

Margin

Low

Capital Intensity

High

Location

Denver, Colorado

Business Type

Life Style

Canine Biologics, with a valuation of $6.1 million, is raising funds on NetCapital. The company makes nutrition products to support dogs battling cancer. It uses the highest-quality ingredients, top-tier expertise, and inspired thinking to make pet nutrition products with specialized supplements, vitamins, and minerals. Canine Biologics is a unique company with an expanded product roadmap, including a liquid diet for dogs and formulated treats. Jeff Sutherland founded Canine Biologics in 2019. The current crowdfunding campaign has a minimum target of $10,000 and a maximum target of $477,540. The campaign proceeds will be used for new product development, inventory purchases, selling and marketing costs, administrative costs, and compensation for managers.

Summary Profit and Loss Statement

Most Recent Year Prior Year

Revenue

$5,823

$0

COGS

$5,650

$0

Tax

$0

$0

 

 

Net Income

$-353,517

$-10,497

Summary Balance Sheet

Most Recent Year Prior Year

Cash

$98,886

$119,551

Accounts Receivable

$25,894

$0

Total Assets

$403,282

$146,911

Short-Term Debt

$33,296

$8,409

Long-Term Debt

$0

$0

Total Liabilities

$33,296

$8,409

Financials as of: 09/08/2021
Create a free account today to gain access to KingsCrowd analytics.

Raise History

Offering Name Close Date Platform Valuation/Cap Total Raised Security Type Status Reg Type
Canine Biologics 03/07/2022 Netcapital $6,123,284 $39,141 Equity - Common Funded RegCF
Canine Biologics 08/13/2021 Wefunder $6,500,000 $57,571 SAFE Funded RegCF
Create a free account today to gain access to KingsCrowd analytics.

Price per Share History

Note: Share prices shown in earlier rounds may not be indicative of any stock splits.

Valuation History

Revenue History

Note: Revenue data points reflect the latest of either the most recent fiscal year's financials, or updated revenues directly from the founder, at each raise's close date.

Employee History

Upgrade to gain access

Pay Monthly
Annually (Save 17%)

Edge

$25 /month
billed annually
Free portfolio tracking, data-driven ratings, AI analysis and reports
Plan Includes:
Everything in Free, plus
Company specific KingsCrowd ratings and analyst reports
Deal explorer and side-by-side comparison
Startup exit and failure tracking
Startup market filters and historical industry data
Advanced company search ( with ratings)
Get Edge Annual
Already a member? Log in here.

Ratings KingsCrowd Startup Rating Methodology Article

Blurred Ratings Bars Blurred Ratings Bars
Founders: enhance your startup's credibility on KingsCrowd. Create an account to claim this raise page.
Add to portfolio
Canine Biologics on NetCapital 2021
Platform: Netcapital
Security Type: Equity - Common
Valuation: $6,123,284
Price per Share: $0.81

Follow company

Follow Canine Biologics on NetCapital 2021

Buy Canine Biologics's Deal Report

Warning: according to the close date for this deal, Canine Biologics may no longer be accepting investments.

Canine Biologics Deal Report

Get KingsCrowd’s comprehensive report on Canine Biologics including:

  • How our proprietary algorithm rates their current capital raise (1-5 stars)
  • Detailed price, market, team, differentiators, performance, and risk ratings
  • Whether Canine Biologics is undervalued or overvalued
  • Scores on the founding team and key personnel's background and expertise

Buy the Canine Biologics deal report for only $10!

Email address:
Looking to buy more than one deal report? Get unlimited reports by upgrading to Edge